|
|
|
|
|
||||||
|
LE Magazine Special
Edition, Winter 2004/2005 In recent years, the beneficial effects of genistein and other soy isoflavones have been shown in numerous published studies. The most prestigious study was published in Journal of the National Cancer Institute and involved 21,852 Japanese women. The findings revealed that the women with the most isoflavones in their diet had the lower risk for developing undesirable breast cell colonies.3 This confirms a myriad of published studies that revealed those who consume the most soy have much lower rates of undesirable cell colonies.4-7 In response to increasing evidence that other constituents of soy may provide significant cell protective affects, a new formulation has been developed that provides the same standardized isoflavone extract that members have been using for the past seven years, plus fermented soy natto that may provide additional benefits. Soy natto enhances
isoflavone absorption and provides other nutrients contributed by the
fermentation process.9,10 The enhanced absorption of genistein, daidzein,
etc. may be significant enough that only one capsule of the new Super
Absorbable Soy Isoflavones is required each day. Based on studies of Japanese dietary isoflavone food consumption, just one capsule of the new Super Absorbable Soy Isoflavones provides more genistein and daidzein (50 mg) than the average Japanese person consumes in their diet.12-15 The typical American diet, on the other hand, often provides less than 1 mg of these cell-protecting isoflavones.16 Compared to the Mega Soy Extract product, the new Super Absorbable Soy Isoflavones provides a much more complete soy supplement, but does not cost any more than the Mega Soy Extract product. Please note that
Mega Soy Extract capsules (containing only isoflavones and no natto
extract) are still available for those who prefer to use this particular
formula. 2. Dietary Phytochemicals in Cancer Prevention and Treatment, Vol 401 of Advances in Experimental Medicine and Biology, 1996. Ch. 7: Soy Isoflavavonoids and Cancer Prevention, 87-100. 3. Yamamoto S, Sobue T, Kobayashi M, et al. Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst. 2003 Jun 18;95(12):906-13. 4. Lee HP, Gourley L, Duffy SW, et al. Dietary effects on breast cancer risk in Singapore. Lancet. 1991 May 18;337(8751):1197-200. 5. Hirose K, Tajima K, Hamajima N. A large-scale, hospital-based case control study of risk factors of breast cancers according to menopausal status. Japan J Cancer Res. 1995 Feb;86(2):146-54. 6. Setchell KD. Soy isoflavonesbenefits and risks from natures selective estrogen receptor modulators (SERMs). J Am Coll Nutr. 2001 Oct;20(5):354S-362S. 7. Horn-Ross PL, John EM, Canchola AJ, et al. Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst. 2003 Aug 6;95(15):1158-64. 8. Sonoda T, Nagata Y, Mori M, et al. A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci. 2004 Mar;95(3):238-42. 9. Slavin JL, Karr SC, Hutchins AM, et al. Influence of soybean processing, habitual diet, and soy dose on urinary isoflavonoid excretion. Am J Clin Nutr. 1998 Dec;68(6 Suppl):1492S-1495S. 10. Hutchins AM, Slavin JL, Lampe JW. Urinary isoflavonoid phytoestrogen and lignan excretion after consumption of fermented and unfermented soy products. J Am Diet Assoc. 1995 May;95(5):545-51. 11. Gotoh T, Yamada K, Ito A, et al. Chemoprevention of N-nitroso-N-methylurea-induced rat mammary cancer by miso and tamoxifen, alone and in combination. Jpn J Cancer Res. 1998 May;89(5):487-95. 12. Arai Y, Uehara M, Sato Y, et al. Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake. J Epidemiol. 2000 Mar;10(2):127-35. 13. Wakai K, Egami I, Kato K, et al. Dietary intake and sources of isoflavones among Japanese. Nutr Cancer. 1999;33(2):139-45. 14. Kimira M, Arai Y, Shimoi K, et al. Japanese intake of flavonoids and isoflavonoids from foods. J Epidemiol. 1998 Aug;8(3):168-75. 15. Wu AH, Yu MC, Tseng CC, et al. Plasma isoflavone levels versus self-reported soy isoflavone levels in Asian-American women in Los Angeles County. Carcinogenesis. 2004 Jan;25(1):77-81. Epub 2003 Oct 10. 16. de Kleijn MJ, van der Schouw YT, Wilson PW, et al. Intake of dietary phytoestrogens is low in postmenopausal women in the United States: the Framingham study(1-4). J Nutr. 2001 Jun;131(6):1826-32. Regenezyme Organic Soybean Sprout Concentrate, Soy Extract Powder, Mega Soy Extract, Soy Plus Protein Powder (Vanilla), Soy Protein Supro Protein Powder, Soy Power Powder, Ultra Soy Extract, Soy Isoflavones.
LE Magazine
July 2004 Over the last year, the results of these studies began to be released. While ignored by the mainstream media, the startling findings indicate that prostate and breast cancer risk could be cut in half if people only consumed more soy. One of every two American men will develop cancer in his lifetime, as will one of every three American women. Despite billions of research dollars spent, the epidemic of cancer continues. A small but growing number of leading cancer researcherssuch as Dr. Samuel S. Epstein, head of the National Cancer Prevention Coalitionare calling for a major change in how the federal government fights cancer. Epstein and other advocates of cancer prevention emphasize that cancer is a multistage disease that is amenable to prevention in its earliest stages of development. One of the most widely available means of cancer preventionyet generally overlooked by major cancer organizations and mainstream medicineis the use of natural chemopreventive agents. Numerous components found in fruits and vegetables might contribute to their ability to reduce the risk of cancer, including dietary fiber, micronutrients, and various phytochemicals . . . the biomedical community needs to recognize and advocate approaches to prevent cancer [such as the use of natural chemopreventive agents] with the same enthusiasm that it currently directs toward treating it.1 Soy: A Powerful
Chemopreventive Agent Soy, Estrogen,
and Breast Cancer In fact, soy isoflavones do not simply act as natural estrogens. Soy isoflavones are correctly classified as selective estrogen receptor modulators. Due to their unique molecular structure, soy isoflavones can act as either estrogen receptor agonists or receptor blockers. With this ability, soy isoflavones are thought by many to confer the beneficial effects of estrogen without its potentially dangerous side effects, especially in hormonally sensitive tissues found in both the breast and endometrium.5,6 Despite the evidence-based research showing soy isoflavones preventive effects on breast cancer, along with epidemiological studies highlighting the much lower rates of breast cancer among Asian women who consume significant amounts of soy-based products, some doctors still caution women against using soy-based foods and supplements. They contend that because soy isoflavones have been labeled as estrogen mimics, they could potentially worsen or even cause breast cancer. With the current knowledge that soy isoflavones act as selective estrogen receptor modulators and are not simply estrogen mimics, these arguments simply do not hold up. As the authors of a recent study of soy isoflavones stated: In addition to being
a chemoprotective supplement for breast cancer, soy isoflavones also
are thought to be effective in warding off other types of cancer that
afflict women, including endometrial cancer. A recent case-control study
reported the effects of soy isoflavones and other phytoestrogens on
the risk of developing endometrial cancer.11 The study compared 500
women aged 35-79 who developed endometrial cancer between 1996 and 1999
to 470 age-and ethnicity-matched controls. As in studies examining the
effects of isoflavones on breast cancer, this study showed that women
who had a higher intake of soy isoflavones had a significantly lower
risk of developing endometrial cancer. Even more interesting was that
the levels of isoflavones needed to provide protection against endometrial
cancer were found to be much lower than the amount believed necessary
to protect against breast cancer. Soy Counteracts
Prostate Cancer in Men Most recently, in a study published in the journal Cancer Science in March 2004, researchers found that soybean products, as well as other Far Eastern dietary staples such as fish and tofu, were associated with a decreased risk of prostate cancer in Japanese men.13 Specifically, men who consumed the greatest amounts of soybeans and tofu were 47% and 53% less likely, respectively, to develop prostate cancer than those who consumed the smallest amounts. Furthermore, in men who consumed the greatest amount of the fermented soybean natto, the prostate cancer incidence was reduced a remarkable 75%. Newly published animal research lends strong support to this hypothesis. In a study published in January 2004, University of Colorado researchers fed inositol hexaphosphate (IP6), a dietary phytochemical found in cereals, soy, legumes, and other fiber-rich foods, to mice that had been injected with prostate cancer cells. Compared to controls, the mice fed IP6 exhibited suppressed hormone-refractory prostate cancer growth by as much as 66% when compared to littermates without the IP6-enriched diet.15 In another study published in March 2004, Japanese researchers evaluated the effects of Fuji-flavone, a commercial isoflavone supplement derived from soybean products, on rat prostate carcinogenesis. Rats fed a diet containing Fujiflavone showed a significantly lower incidence of prostate carcinomas than those fed a soy-free diet, leading the researchers to conclude that intake of dietary isoflavones can be promising for prevention of human prostate cancer.16 While animal-based studies are important in advancing scientific knowledge, not all results from animal studies are directly transferable to humans. Fortunately, human studies (in addition to the previously noted epidemiological reports) also support the theory that soy isoflavones can protect men against prostate cancer. One of the largest of these, a prospective study conducted between 1976 and 1992 on 12,395 men in Loma Linda, California, found that men who drank a glass of soy milk more than once a day reduced their risk of prostate cancer 70% compared to men who did not drink soy milk.17 Even after adjusting for various statistical confounders, the 70% reduction held firm, leading the authors to conclude that our study suggests that men with high consumption of soy milk are at decreased risk of prostate cancer. This may also be the case for men who frequently consume other soy products with intact content of isoflavones . . . Prevention:
The Key Despite decades of effort and the expenditure of billions of dollars on research, the war on cancer in America has produced little more than an increasingly lethal stalemate. While the medical establishment remains fixated on cancer diagnosis and treatment, a growing legion of researchers is calling for new approaches, with an emphasis on preventing cancer through the use of natural chemopreventive agents such as those found in fruits and vegetables. Among the most powerful
of these natural chemopreventive agents is soy. Soy and soy-based supplements
can aid in the prevention of a variety of significant diseases, including
breast, prostate, and endometrial cancers, as well as heart disease.
New studies suggest that soy may even provide protection against premature
skin aging and help lower harmful low-density lipoprotein (LDL) cholesterol.
In fact, each passing month seems to produce new research heralding
soys remarkable disease-fighting and health-promoting effects. Positive
Effects on Skin Aging, Cholesterol Multiple studies now show that soy isoflavones also reduce harmful levels of cholesterol and the resulting atherosclerosis. Asian men, who consume much more soy than Americans, have a sixfold lower mortality rate for coronary heart disease compared to American men. The difference also is seen in Asian women, who have an eightfold lower mortality rate from heart disease compared to their US counterparts. Animal studies have confirmed that soy isoflavones have significant effects in lowering harmful LDL cholesterol,20 as have studies in humans. In two recent studies at the University of Minnesota, women aged 18-70 who were given soy isoflavone supplements saw a marked decrease in their LDL cholesterol.21,22 An even more recent Canadian study examined the effects of soy isoflavones on cholesterol and homocysteine levels, as well as on blood pressure, in 41 men and women.23 In this randomized crossover study, patients were fed a low-fat dairy-based diet, a diet low in soy isoflavones, or a diet high in soy isoflavones. After three months, the men and women who ate either the low- or high-isoflavone diet had significantly lower LDL cholesterol and homocysteine levels, as well as a reduction in blood pressure, compared to those who ate the low-fat dairy-based diet. This led the study authors to conclude that soy protein foods, regardless of their isoflavone content, may improve many lipid and nonlipid risk factors for [coronary artery disease] and thus justify the use of soy foods as part of a dietary strategy to reduce [coronary artery disease] risk. With strong scientific evidence showing that soy isoflavones can help prevent breast, endometrial, and prostate cancer, as well as protect both men and women against heart disease, physicians should not hesitate to educate their patients on the need to incorporate soy in their diets. Soy isoflavones not only protect against the two most common and deadly killers in America today, but clinical research suggests that they also may protect against diabetes and obesity.24,25 A small, nondescript legume, soy nevertheless continues to provide us with a bountiful harvest of health benefits.
2. Messina MJ. Legumes and soybeans: overview of their nutritional profiles and health effects. Am J Clin Nutr. 1999 Sep;70(3 Suppl):439S-50S. 3. Yamamoto S, Sobue T, Sasaki S, et al. Validity and reproducibility of a self- administered food-frequency questionnaire to assess isoflavone intake in a Japanese population in comparison with dietary records and blood and urine isoflavones. J Nutr. 2001 Oct;131(10):2741-7. 4. Barnes S. Effect of genistein on in vitro and in vivo models of cancer. J Nutr. 1995 Mar;125(3 Suppl):777S-83S. 5. Jordan VC, Morrow M. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev. 1999 Jun; 20(3):253-78. 6. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA. 1999 Jun 16;281:2189-97. 7. Lee HP, Gourley L, Duffy SW, Esteve J, Day NE. Dietary effects on breast cancer risk in Singapore. Lancet. 1991 May 18;337(8751):1197-00. 8. Hirose K, Tajima K, Hamajima N. A large-scale, hospital-based case control study of risk factors of breast cancers according to menopausal status. Japan J Cancer Res. 1995 Feb;86(2):146-54. 9. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S. Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst. 2003 Jun 18;95(12):906-13. 10. Setchell KD. Soy isoflavonesbenefits and risks from natures selective estrogen receptor modulators (SERMs). J Am Coll Nutr. 2001 Oct;20(5):354S-62S. 11. Horn-Ross PL, John EM, Canchola AJ, Stewart SL, Lee MM. Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst. 2003 Aug 6;95(15):1158-64. 12. Spitz M, Strom Y, Yamura Y, et al. Epidemiologic determinants of clinically relevant prostate cancer. Int J Cancer. 2000 May 20;89(3):259-64. 13. Sonoda T, Nagata Y, Mori M, et al. A case-control study of diet and prostate cancer in Japan: possible protective effect of tradition- al Japanese diet. Cancer Sci. 2004 Mar;95(3):238-42. 14. Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK. Soybean phyto- chemicals inhibit the growth of trans-plantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr. 1999 Sep;129(9):1628-35. 15. Singh RP, Sharma G, Mallikarjuna GU, Dhanalakshmi S, Agarwal C, Agarwal R. In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):244-50. 16. Hikosaka A, Asamoto M, Hokaiwado N, et al. Inhibitory effects of soy isoflavones on rat prostate carcinogenesis induced by 2-amino- 1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Carcinogenesis. 2004 Mar;25(3):381- 7. Epub 2003 Dec 04. 17. Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Controls. 1998 Dec;9(6):553-7. 18. Ozasa K, Nakao M, Watanabe Y, et al. Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci. 2004 Jan;95(1):65-71. 19. Wei H, Saladi R, Lu Y, et al. Isoflavone genistein: photoprotection and clinical implications in dermatology. J Nutr. 2003 Nov;133(11 Suppl):3811S-19S. 20. Anthony MS, Charkson TB, Williams JK. Effects of soy isoflavones on atherosclerosis: potential mechanisms. Am J Clin Nutr. 1998 Dec;68(6 Suppl):1390S-3S. 21. Merz-Demlow BE, Duncan AM, Wangen KE, et al. Soy isoflavones improve plasma lipids in normocholesterolemic, pre-menopausal women. Am J Clin Nutr. 2000 Jun;71(6):1462-9. 22. Wangen KE, Duncan AM, Xu X, Carr TP, Kurzer MS. Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemmic postmenopausal women. Am J Clin Nutr. 2001 Feb;73(2):225- 31. 23. Jenkins DJA, Kendall CWC, Jackson CC, et al. Effects of high- and low-isoflavone soy foods on blood lipids, oxidized LDL, homo- cysteine, and blood pressure in hyperlipi- demic men and women. Am J Clin Nutr. 2002 Aug;76(2):365-72. 24. Bhathena SJ, Velasquez MT. Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr. 2002 Dec;76(6):1191-201. 25. Lund TD, Munson
DJ, Haldy ME, Setchell KDR, Lephart ED, Handa RJ. Equol is a novel anti-androgen
that inhibits prostate growth and hormone feedback. Biol Reprod. 2004
Apr;70(4):1188-95.
|
||||||
|
|
||||||
|
These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease
|
||||||